Pfizer Japan launched Tucatinib ethanol adduct tablets (Tukysa®) on April 21, 2026, for patients with HER2-positive unresectable or recurrent breast cancer who have prior chemotherapy.
Drug approval timeline reflects international precedent
Tucatinib received manufacturing and marketing approval in Japan in February 2026 after an application submitted in March 2025, and was added to the NHI drug price standard in April 2026. The drug had already been approved by the U.S. FDA in April 2020 and the EMA in February 2021.
Clinical benefit shown in heavily pretreated population
In the HER2CLIMB phase 2 trial, tucatinib combined with trastuzumab and capecitabine significantly improved progression-free survival, overall survival, and intracranial progression-free survival in patients with brain metastases compared to placebo, based on blinded independent central review. The most common adverse events were diarrhea, hand-foot syndrome, nausea, vomiting, and stomatitis.
Unmet need remains after prior anti-HER2 therapy
HER2-positive breast cancer accounts for 15% to 20% of all breast cancers in Japan, where approximately 99,000 women were newly diagnosed in 2021. Despite advances in anti-HER2 therapies, most patients experience disease progression afterward, and no standardized subsequent treatment has been established.
Who is eligible for Tucatinib under this approval?
Patients with HER2-positive unresectable or recurrent breast cancer who have received prior chemotherapy are eligible for Tucatinib treatment under the current approval.
How does Tucatinib differ from existing HER2-targeted therapies?
Tucatinib is an oral HER2 tyrosine kinase inhibitor designed to selectively target HER2 with minimal effect on EGFR, showing activity in patients with brain metastases and those who have progressed on trastuzumab, pertuzumab, and T-DM1.